Israel Englander Kymera Therapeutics, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 38,006 shares of KYMR stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,006

Previous 18,286 107.84%

Holding current value

$1.79 Million

Previous $545,000 229.91%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$30.16 - $52.4 $594,755 - $1.03 Million	19,720 Added 107.84%	38,006 $1.8 Million
Q2 2024 Aug 14, 2024	SELL	$29.85 - $39.42 $1.04 Million - $1.37 Million	-34,766 Reduced 65.53%	18,286 $545,000
Q1 2024 May 15, 2024	SELL	$22.9 - $43.57 $1.04 Million - $1.97 Million	-45,244 Reduced 46.03%	53,052 $2.13 Million
Q4 2023 Feb 14, 2024	BUY	$10.97 - $26.84 $472,752 - $1.16 Million	43,095 Added 78.07%	98,296 $2.5 Million
Q2 2023 Aug 14, 2023	BUY	$22.4 - $34.92 $1.24 Million - $1.93 Million	55,201 New	55,201 $1.27 Million
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $1.44 Million - $2.37 Million	69,085 New	69,085 $1.5 Million
Q2 2021 Aug 16, 2021	SELL	$31.08 - $51.95 $3.97 Million - $6.64 Million	-127,727 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$35.64 - $85.46 $4.55 Million - $10.9 Million	127,727 New	127,727 $4.96 Million
Q4 2020 Feb 16, 2021	SELL	$28.07 - $87.83 $449,344 - $1.41 Million	-16,008 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$26.1 - $33.28 $417,808 - $532,746	16,008 New	16,008 $517,000

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.57B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account